| __timestamp | BioMarin Pharmaceutical Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 17986000 |
| Thursday, January 1, 2015 | 402271000 | 32480000 |
| Friday, January 1, 2016 | 476593000 | 68081000 |
| Sunday, January 1, 2017 | 554336000 | 169906000 |
| Monday, January 1, 2018 | 604353000 | 248932000 |
| Tuesday, January 1, 2019 | 680924000 | 354100000 |
| Wednesday, January 1, 2020 | 737669000 | 433300000 |
| Friday, January 1, 2021 | 759375000 | 583300000 |
| Saturday, January 1, 2022 | 854009000 | 752700000 |
| Sunday, January 1, 2023 | 937300000 | 887600000 |
| Monday, January 1, 2024 | 1009025000 | 1007200000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing operational costs is crucial for sustained growth. Over the past decade, BioMarin Pharmaceutical Inc. and Neurocrine Biosciences, Inc. have demonstrated contrasting strategies in their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, BioMarin's SG&A expenses grew steadily, peaking at approximately 937 million USD in 2023, reflecting a 210% increase from 2014. This consistent rise suggests a strategic investment in administrative capabilities and market expansion. In contrast, Neurocrine Biosciences started with a modest 18 million USD in 2014 but saw a staggering increase of nearly 4,800% by 2023, reaching 888 million USD. This dramatic rise indicates aggressive scaling and market penetration efforts.
These trends highlight the diverse approaches biotech companies take in managing operational costs, offering valuable insights into their strategic priorities and market positioning.
SG&A Efficiency Analysis: Comparing Pfizer Inc. and BioMarin Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Sanofi or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Novavax, Inc.
BioMarin Pharmaceutical Inc. and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.